DAVID BALTIMORE - 30 Jan 2025 Form 4 Insider Report for Regulus Therapeutics Inc. (RGLS)

Role
Director
Signature
Christopher Aker, Attorney in Fact
Issuer symbol
RGLS
Transactions as of
30 Jan 2025
Net transactions value
+$20,787
Form type
4
Filing time
31 Jan 2025, 17:00:06 UTC
Previous filing
21 May 2024
Next filing
30 Apr 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RGLS Common Stock Purchase $20,787 +19,610 +766% $1.06 22,169 30 Jan 2025 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The weighted average purchase price for the transaction reported was $1.06, and the range of prices were between $0.97 and $1.15. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each price will be provided.